SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centrus shares are drawing attention amid a steep, volatile selloff, with traders blaming share dilution from equity and warrant offerings, a rich valuation, and the cost and execution risks of expanding enrichment capacity. Bulls counter that DOE and commercial fuel contracts support the longer-term domestic nuclear-fuel and HALEU opportunity, while bearish traders question when that growth will translate into results.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A breakout to fresh 52-week highs ahead of the Q3 report has traders focused on BRIUMVIs sales momentum and the possibility of stronger guidance. The community also points to heavy call activity and short interest, while debating whether the rally reflects earnings positioning and momentum or unconfirmed buyout speculation; upcoming subcutaneous BRIUMVI data is another catalyst in view.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA accelerated approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about competition for Precigens PAPZIMEOS and prompted debate over its potential effect on sales. Traders weigh the rivals dosing advantages against PAPZIMEOS commercial head start, established payer access and stronger first-year response data, while also watching Precigens upcoming earnings for evidence of continued uptake.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs large equity raise and stock-funded Elisity acquisition have put dilution and capital allocation at the center of discussion as shares sell off. Some traders see the deal as extending the company into cybersecurity and broader quantum infrastructure, while others question its value per share and want evidence that acquisitions and quantum programs can translate into recurring revenue.

Twilio, Inc. engages in the development of communications software, cloud-based platforms, and services. It operates through Twilio Communications and Twilio Segments. The Twilio Communications segment includes the platforms Messaging and Voice. The Twilio Segment involves Segment, Engage, Flex, Email, and others. The company was founded by John Wolthuis, Jeffery G. Lawson, and Evan Cooke in March 2008 and is headquartered in San Francisco, CA.

Twilio Inc - Ordinary Shares Class A

Twilio Inc

Twilios post-earnings selloff follows a Q3 beat and higher full-year outlook, as its Q4 organic growth guidance signaled a slowdown from the prior quarter. Traders are divided between viewing the drop as an overreaction with bounce potential and waiting for the stock to stabilize as investors reassess the growth outlook.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbases selloff is being tied to Q3 results that beat on headline EPS but showed weaker trading revenue and operating performance, with much of reported profit attributed to gains on crypto holdings; the Binance hack and broader crypto-market weakness have added pressure. Traders disagree on whether the breach could send users to Coinbase or deepen concerns about exchange security and crypto demand.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarnas steep post-earnings slide and persistent weak trading dominate the discussion, with traders debating whether concerns about guidance, profitability and ongoing selling pressure explain the decline or whether the stock is oversold ahead of Q3 results. Bulls cite Apple and payments partnerships and longer-term BNPL growth, while frustrated holders question why the shares keep lagging.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

The European Lithium acquisition and resulting CRML share issuance are driving debate, with some traders concerned about dilution and potential selling pressure while others see the added cash and assets, including greater ownership of Tanbreez, as a positive. High-borrow-cost and short-squeeze speculation is also prominent, though traders disagree on whether it will lead to sustained buying.

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,105,365. The last known price of Bitcoin is 78,059.66839082 USD and is up 0.67 over the last 24 hours. It is currently trading on 12773 active market(s) with $13,095,082,899.62 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

The massive Binance hack and the exchanges resumption of withdrawals have put crypto security, customer outflows, and potential market contagion at the center of Bitcoin discussion. Traders are divided: bears warn of further selling and exchange-liquidity risks, while bulls argue Bitcoins resilience through the incident supports a recovery.

TRON (TRX) is a cryptocurrency launched in 2018. TRON has a current supply of 95,023,844,090.614844 with 95,023,861,343.880544 in circulation. The last known price of TRON is 0.3125405 USD and is up 1.67 over the last 24 hours. It is currently trading on 1389 active market(s) with $1,085,916,839.31 traded over the last 24 hours. More information can be found at https://trondao.org/.

Tron

TRONs steady price action and relative resilience versus other cryptocurrencies are drawing attention, with traders debating whether consolidation signals another breakout or a corrective pullback. Some also point to the networks role in stablecoin transfers as support for the longer-term bullish case, while others remain frustrated by its subdued moves.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TEVA Gets FDA Nod for Weltruza as Once-Monthly LAI in Schizophrenia

Teva wins FDA approval for Weltruza, the first once-monthly subcutaneous olanzapine injection for adults with schizophrenia, with a U.S. launch expected soon.

AbbVie's Temab-A Gets Two FDA Breakthrough Therapy Tags in Cancer

ABBV's Temab-A wins two FDA Breakthrough Therapy designations for treating colorectal cancer and non-small cell lung cancer.

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Grows By 40.1%

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totaling 914,989 shares, an increase of 40.1% from the March 31st total of 653,203 shares. Currently, 12.6% of the company's...

HC Wainwright Reiterates "Buy" Rating for Actuate Therapeutics (NASDAQ:ACTU)

HC Wainwright reaffirmed a "buy" rating and set a $15.00 target price on shares of Actuate Therapeutics in a research note on Wednesday...

Why Did Actuate Therapeutics (ACTU) Stock Jump Over 14% After Hours?

Actuate Therapeutics shares surged 14.41% after-hours after Nature Medicine published Phase 2 data showing elraglusib plus chemotherapy improved overall survival in metastatic pancreatic cancer.read...

Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Actuate Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU

Voss Capital LP raised its holdings in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 213.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities...

Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen downgraded shares of Actuate Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded Actuate Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...

Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX.

Actuate Therapeutics Inc.

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer

Equity

Neutral Sentiment

Actuate Therapeutics, Inc. (ACTU) announced on Monday that it has amended its application to the U.S. Food and Drug Administration (FDA) for its lead investigational drug Elraglusib in the treatment of pancreatic cancer.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html">stated</a> that it has amended the investigational new drug (IND) application with updated clinical data from its ongoing international mid-stage trial of the drug in the first-line treatment of metastatic pancreatic cancer. The study showed a statistically significant improvement in median overall survival with the combination arm of Elraglusib plus Gemcitabine/nab-paclitaxel (GnP) versus GnP alone, in addition to a 37% reduction in the risk of death.The data is intended to support planned regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) beginning later this year and continuing into early 2026, the company said. It also added that the data strengthens the case for Elraglusib as a back-bone therapy that can be combined with different regimens used to treat pancreatic cancer.The company is currently studying Elraglusib in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapies.<a href="https://stocktwits.com/symbol/ACTU">ACTU shares</a> traded 6% higher at the time of writing. On Stocktwits, retail sentiment around ACTU jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_11_15_37_AM_png_49248344ea.webp" alt="ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Actuate also stated that its recent $17.25 million public offering provides an extended runway into the second half of 2026.“We have already updated the clinical data package on file with the FDA, and during the remainder of this year and into the first quarter of 2026, we expect to gain clarity on Elraglusib’s regulatory path forward for the first-line treatment of metastatic PDAC,” said CEO Daniel Schmitt.ACTU stock is down by 11% this year but up by 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rallies-after-piper-sandler-hikes-price-target/chDQA76R32Z">Tesla Stock Rallies After Piper Sandler Hikes Price Target – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 

iShares Russell 2000 BuyWrite ETF

Vanguard Russell 2000 Growth ETF

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ACTU Big hit here afterhours on a huge offering - basically triples the amount of shares. 
 
In theory sounds bad but a lot of these huge offering situation end up playing as it portends overall good news. Note this comes on the heels of an announcement this morning that they'll be presenting trial data at a conference in a few weeks...

Brian Badtrader

$ACTU there has to be a RS here... as they need to raise capital.... New money will not want a stock price under 1 dollar for a potential de-list... wait for big money to come in

Long and Strong

$ACTU congrats on bankrupting another biotech stock trying to cure Cancer shorty - 
your Mom must be soooooo proud.

Mac Odell

$ACTU My mistake about data presentation upcoming, I was looking at the wrong ticker's news.  
  
They offering part is accurate... and definitely still interesting that they went so big with it. Seems like that should normally inflict a bigger hit than just 23% down... delayed reaction or is there something cooking behind the scenes???

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACTU Actuate Therapeutics Inc.

Fundamentals

Latest ACTU News